Welcome!

News Feed Item

Biologicals in Oncology Drug Pipeline Update 2013

NEW YORK, Aug. 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biologicals in Oncology Drug Pipeline Update 2013

http://www.reportlinker.com/p0379872/Biologicals-in-Oncology-Drug-Pipeli...

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies.

There are today 881 companies plus partners developing 1527 biological drugs in 3359 developmental projects in cancer. In addition, there are 24 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 889 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 604 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 82 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.Drug Pipeline Update at a Glance

InvestigatorsIncludes more than 881 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.

Drug name & SynonymsLists commercial, generic and code names for drugs.

Developmental stage

This Drug Pipeline Update contains 1527 biological drugs in development, which have a total of 3359 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs

Marketed# 141

Registered# 2

Pre-registration# 9

Phase III# 109

Phase II# 371

Phase I# 405

Preclinical# 935

No Data# 12

Suspended# 24

Ceased# 889

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.

Indications

Included biological drugs are also in development for 337 other indications, where of 115 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.

TargetsMutationsAll targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

Biological Structures

The identity of available biological structures on 349 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 4087 structures available today among drug targets.

Identified drugs are linked to more than 604 different targets, divided into 82 classifications of molecular function:- Acid phosphatase activity- Antigen binding- ATPase activity- Auxiliary transport protein activity- B cell receptor activity- Binding- Carboxy-lyase activity- Carboxypeptidase activity- Catalytic activity- Cell adhesion molecule activity- Chaperone activity- Chemokine activity- Cofactor binding- Complement activity- Cysteine-type peptidase activity- Cytokine activity- Cytoskeletal protein binding- Deaminase activity- Defense/immunity protein activity- DNA binding- DNA repair protein- DNA topoisomerase activity- DNA-directed DNA polymerase activity- DNA-directed RNA polymerase activity- DNA-methyltransferase activity- Extracellular ligand-gated ion channel activity- Extracellular matrix structural constituent- Fucosyltransferase activity- G-protein coupled receptor activity- Growth factor activity- Growth factor binding- GTPase activator activity- GTPase activity- Guanylate cyclase activity- Heat shock protein activity- Hormone activity- Hydrolase activity- Intracellular ligand-gated ion channel activity- Isomerase activity- Kinase activity- Kinase binding- Kinase regulator activity- Ligand-dependent nuclear receptor activity- Ligase activity- Lipid kinase activity- Lipid phosphatase activity- Metallopeptidase activity- MHC class I receptor activity- Molecular function unknown- Motor activity- Oxidoreductase activity- Peptidase activity- Peptide hormone- Peroxidase activity- Protease inhibitor activity- Protein binding- Protein serine/threonine kinase activity- Protein threonine/tyrosine kinase activity- Protein tyrosine/serine/threonine phosphatase activity- Protein-tyrosine kinase activity- Receptor activity- Receptor binding- Receptor signaling complex scaffold activity- Receptor signaling protein serine/threonine kinase activity- Receptor signaling protein tyrosine phosphatase activity- RNA binding- RNA-directed DNA polymerase activity- Serine-type peptidase activity- Signal transducer activity- Structural constituent of cytoskeleton- Structural molecule activity- Superoxide dismutase activity- T cell receptor activity- Transcription factor activity- Transcription regulator activity- Transferase activity- Translation regulator activity- Transmembrane receptor activity- Transmembrane receptor protein tyrosine kinase activity- Transporter activity- Ubiquitin-specific protease activity- Unclassified

Sub-Cellular Localization

Identified targets are categorized into 38 different primary and alternate sub-cellular localizations:

- Apical membrane

- Cell junction

- Cell surface

- Centrosome

- Clathrin-coated vesicle

- Cytoplasm

- Cytoplasmic vesicle

- Cytoskeleton

- Cytosol

- Early endosome

- Endoplasmic reticulum

- Endosome

- Extracellular

- Extracellular matrix

- Golgi apparatus

- Golgi membrane

- Immunological synapse

- Integral to membrane

- Kinetochore

- Late endosome

- Lysosome

- Membrane fraction

- Microtubule

- Mitochondrial matrix

- Mitochondrial membrane

- Mitochondrion

- Nucleolus

- Nucleus

- Perinuclear region

- Perinuclear vesicle

- Peroxisomal matrix

- Plasma membrane

- Sarcoplasmic reticulum

- Secreted

- Secretory granule

- Secretory vesicle

- Soluble fraction

- Vesicle

Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.

Target Expression Profile

Direct links are provided from inside the application to 716 protein expression profiles of 470 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:

- 48 different normal tissue types

- 20 different types of cancer

- 47 cell lines

- 12 samples of primary blood cells

Pathway ReferalsIdentified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.- BioCarta# 265 Pathways- KEGG# 194 Pathways- NCI-Nature# 251 Pathways- NetPath# 32 Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.

MechanismIn total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.

CompoundIdentified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.

Drug Profile

Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:

Drug Name & SynonymsPresentation of drug name and synonyms

Principal Company & Partners

Presentation of principal company and partners

Target and Molecular Function of TargetDescribed target(s) is/are presented with:Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function

Target Localization

Described target(s) is/are presented with primary and alternate localizations.

Target Expression Profiles

Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:

48 different normal tissue types

20 different types of cancer

47 cell lines

12 samples of primary blood cells

MutationAll targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.

Biological Structures

The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.

Targeted PathwaysDescribed target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.

Mechanism

Drug mechanism of action

Developmental ProjectsSummary field of developmental projects for the drug, including indication, developmental stage and status.Example:Cancer, myeloma – Phase II Clinical Trial – ActiveCancer, prostate – Phase III Clinical Trial – Ceased

Drug Description

Short introduction to drug

Compound DataCompound type, Chemical name, CAS Number and molecular weight

Patent Data

Available patent information related to the drug is presented here.

Fillings and ApprovalsApprovals and submissionsAnalyst comments

Deals & Licensing

Collaborations and deals

Availability for licensing

Phase IV DataAvailable Phase IV development data, developmental history and scientific data.

Phase III Data

Available Phase III development data, developmental history and scientific data.

Phase II DataAvailable Phase II development data, developmental history and scientific data.

Phase I Data

Available Phase I development data, developmental history and scientific data.

Phase 0 DataAvailable Phase 0 development data, developmental history and scientific data.

Preclinical Data

Available preclinical development data, developmental history and scientific data.

Discovery DataAvailable discovery development data, developmental history and scientific data.

Application Features

Search, Find and Filter Panel with Initial Result Presentation

With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.

Click here for a short video (2m 14s) showing an overview of the filters.

The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.

Click here for a short video (3m 26s) showing an example of an inclusion and exclusion search to create the initial results table.

Direct linkage from inside the application to related internet resources

- Drug data is linked to search engines like Google and PubMed

- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.

- Direct links to company web pages of companies

Dynamic Report GeneratorOur dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.

Click here for a short video (6m12s) showing a typical drug profile

System Requirements- Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)- Browser Application (Internet Explorer)- Internet access (to access related internet resources)

To order this report:Drug_Discovery_and_Development Industry: Biologicals in Oncology Drug Pipeline Update 2013

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Splunk basically takes machine data and we make it usable, valuable and accessible for everyone. The way that plays in DevOps is - we need to make data-driven decisions to delivering applications," explained Andi Mann, Chief Technology Advocate at Splunk and @DevOpsSummit Conference Chair, in this SYS-CON.tv interview at @DevOpsSummit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
"Logz.io is a log analytics platform. We offer the ELK stack, which is the most common log analytics platform in the world. We offer it as a cloud service," explained Tomer Levy, co-founder and CEO of Logz.io, in this SYS-CON.tv interview at DevOps Summit, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
In his session at @DevOpsSummit at 19th Cloud Expo, Robert Doyle, lead architect at eCube Systems, will examine the issues and need for an agile infrastructure and show the advantages of capturing developer knowledge in an exportable file for migration into production. He will introduce the use of NXTmonitor, a next-generation DevOps tool that captures application environments, dependencies and start/stop procedures in a portable configuration file with an easy-to-use GUI. In addition to captur...
Due of the rise of Hadoop, many enterprises are now deploying their first small clusters of 10 to 20 servers. At this small scale, the complexity of operating the cluster looks and feels like general data center servers. It is not until the clusters scale, as they inevitably do, when the pain caused by the exponential complexity becomes apparent. We've seen this problem occur time and time again. In his session at Big Data Expo, Greg Bruno, Vice President of Engineering and co-founder of StackIQ...
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of D...
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, John Jelinek IV, a web developer at Linux Academy, will discuss why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers...
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Dave McCarthy, Director of Products at Bsquare Corporation; Alan Williamson, Principal ...
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
DevOps and microservices are permeating software engineering teams broadly, whether these teams are in pure software shops but happen to run a business, such Uber and Airbnb, or in companies that rely heavily on software to run more traditional business, such as financial firms or high-end manufacturers. Microservices and DevOps have created software development and therefore business speed and agility benefits, but they have also created problems; specifically, they have created software securi...
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
"There is a huge interest in Kubernetes. People are now starting to use Kubernetes and implement it," stated Sebastian Scheele, co-founder of Loodse, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.